Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region

Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Kok Wei Koh, Gary Chin Keong Lee, Wee Siong Teo, Narayanaswamy Venketasubramanian, Chun-Chieh Wang, Radhika Mehta

Article Type

Case Series

Published

The authors share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with non-valvular atrial fibrillation in Southeast Asia through several cases of patients at high risk

Read more

COVID-19 therapy and vaccination: a clinical narrative review

Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio

Article Type

Review

Published

This review discusses how the SARS-CoV-2 pandemic has progressed and surged, and summarizes the safety and efficacy of the most used therapies and vaccines in the light of recent evidence.

Read more

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Article Type

Review

Published

This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.

Read more

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

Andrea Beatriz De Lorenzi, Edgardo Kaplinsky, Marx Rivera Zambrano, Laia Tomás Chaume, Joan Monell Rosas

Article Type

Review

Published

This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.